Maike Stenull

Global Head of Strategy and Business Operations at Johnson & Johnson

As Global Head of Strategy and Business Operations for Global External Innovation, located in New Brunswick (NJ), Maike oversees all aspects of strategy development and operational excellence for the Global External Innovation organization that combines Johnson & Johnson Innovation, the World Without Disease Accelerator group and cross-sector R&D, reporting to Bill Hait.

Maike began her J&J career in Germany in 1990, working for Medical Devices at Ethicon and then Endo Surgery, before moving into the Consumer sector, where she held multiple roles of expanding responsibility, both in Europe and the U.S.

From 2011 to 2014, Maike headed up Finance Controlling for Janssen’s Neuroscience Therapeutic Area (TA), providing financial leadership to the TA both for the R&D and Global Commercial areas. She partnered with business leaders in assessing and managing the financial and strategic value of the TA’s R&D pipeline, played a key role in the development of an integrated approach to increasing visibility and transparency of the external innovation portfolio across all TAs and led the organizational re-design of Janssen R&D Finance. Prior to this, Maike played a critical role on the Global Commercial Board, including leading the Long Range Financial Plan for the entire Pharmaceutical sector.

In 2014 she joined the Office of the Chief Medical Officer (OCMO) as a member of the Strategy Realization team. During her time in OCMO, Maike provided project management support for the R&D Management Committee (RDMC) and R&D presentation preparation for the Science, Technology and Sustainability Committee. Additionally, she helped shape and implement several enterprise-wide projects designed to increase operational effectiveness, including the Clinical and Regulatory transformation efforts overseen by Ann Van Dessel and Robin Keen.

Maike holds an MBA from the Wirtschaftsakademie Hamburg, Germany. She is a certified Process Excellence Black Belt (Six Sigma) and she has co-led the GAP (Global Alzheimer’s Platform) work stream focused on alternative Finance options as well as being a founding member of “Women Against Alzheimer’s”.